18F labeled myocardial perfusion PET: New precision in cardiac imaging

PET imaging of heart blood flow has a logistical Achilles’ heel: its best tracers decay almost instantly, tethering scans to an on-site cyclotron. This review covers the workaround that could change that — tracers labeled with fluorine-18.

The longer half-life of 18F tracers, the flagship being flurpiridaz, frees myocardial perfusion PET from the cyclotron, allowing delivery like other radiopharmaceuticals and — importantly — enabling true exercise stress imaging rather than only pharmacologic stress. The authors frame these tracers as a route to both better diagnostic precision and wider PET access.

The practical takeaway is awareness of a near-term shift: if 18F tracers clear regulatory and cost hurdles, cardiac PET could become far more available. The resistance is entrenched SPECT infrastructure and the friction of changing imaging protocols.

We rate the evidence low: a narrative review without original data, and one author discloses imaging-industry ties. Its clinical significance is moderate and contingent — the logistical advantages are genuine, but real-world impact hinges on FDA approval, pricing, and uptake at imaging centers.